Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference

Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that the Company will present updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC) and final results from its Phase 1 cardiac safety trial. The data from both trials will be presented at a poster session during the AACR-NCI -EORTC's "Molecular Targets and Cancer Therapeutics" International Conference in Boston. Picoplatin is a new generation platinum-based chemotherapy agent and the Company's lead product candidate.

Poster presentation details are as follows:

Randomized Phase 2 study of Picoplatin in Combination with 5-fluorouracil and Leucovorin (FOLPI) as a Neuropathy-Sparing Alternative to mFOLFOX-6 as First-line Therapy for Colorectal Cancer (CRC) Abstract #B49 R.L. De Jager, S. V. Cheporov, O. A. Gladkov, M. Y. Biakhov, H. B. Breitz, R. H. Earhart, and the FOLPI Study Group Poster Session B: Clinical Trials 2 Tuesday, November 17, 12:30-2:30 p.m. Eastern Time Halls C-D, Hynes Convention Center QTc Study of Picoplatin with Emphasis on Pharmacodynamics of Cardiac Repolarization Abstract #B212 R. H. Earhart, L. Rosen, D. Mendelson, S. Plaxe, P. Gold, L. Yee, S. Mansoor, C. Verschraegen, A. Phillips, S. Houston, and R.L. De Jager Poster Session B: Pharmacokinetics and Pharmacodynamics 1 Tuesday, November 17, 12:30-2:30 p.m. Eastern Time Halls C-D, Hynes Convention Center
Source:

Poniard Pharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination